Aurobindo Pharma Limited

rs,

(E), MUMBAI -400 051 To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804

Rs 6,473.0 crore

the quarter 5 Consolidated Financial & Business Highlights – Q4 FY23 Revenue from operations at Rs 6,473.0 crore, an increase of 11.4% YoY, US revenues at US$ 370.4 Million Research & Development spend at Rs 410

11.4%

ancial & Business Highlights – Q4 FY23 Revenue from operations at Rs 6,473.0 crore, an increase of 11.4% YoY, US revenues at US$ 370.4 Million Research & Development spend at Rs 410.7 crore in Q4FY23 (6.

370.4 Million

Q4 FY23 Revenue from operations at Rs 6,473.0 crore, an increase of 11.4% YoY, US revenues at US$ 370.4 Million Research & Development spend at Rs 410.7 crore in Q4FY23 (6.3% of revenue) Vs. Rs. 415.2 crore in

Rs 410.7 crore

crore, an increase of 11.4% YoY, US revenues at US$ 370.4 Million Research & Development spend at Rs 410.7 crore in Q4FY23 (6.3% of revenue) Vs. Rs. 415.2 crore in Q3FY23 EBITDA before Forex and Other income at

6.3%

4% YoY, US revenues at US$ 370.4 Million Research & Development spend at Rs 410.7 crore in Q4FY23 (6.3% of revenue) Vs. Rs. 415.2 crore in Q3FY23 EBITDA before Forex and Other income at Rs 1002.2 crore;

Rs. 415.2 crore

t US$ 370.4 Million Research & Development spend at Rs 410.7 crore in Q4FY23 (6.3% of revenue) Vs. Rs. 415.2 crore in Q3FY23 EBITDA before Forex and Other income at Rs 1002.2 crore; EBITDA margin is at 15.5% Net

Rs 1002.2 crore

in Q4FY23 (6.3% of revenue) Vs. Rs. 415.2 crore in Q3FY23 EBITDA before Forex and Other income at Rs 1002.2 crore; EBITDA margin is at 15.5% Net Profit at Rs 505.9 crore Basic & Diluted EPS is Rs 8.64 per share

15.5%

415.2 crore in Q3FY23 EBITDA before Forex and Other income at Rs 1002.2 crore; EBITDA margin is at 15.5% Net Profit at Rs 505.9 crore Basic & Diluted EPS is Rs 8.64 per share Net capex for the quarter

Rs 505.9 crore

EBITDA before Forex and Other income at Rs 1002.2 crore; EBITDA margin is at 15.5% Net Profit at Rs 505.9 crore Basic & Diluted EPS is Rs 8.64 per share Net capex for the quarter ~US$ 105 Million including inv

Rs 8.64

t Rs 1002.2 crore; EBITDA margin is at 15.5% Net Profit at Rs 505.9 crore Basic & Diluted EPS is Rs 8.64 per share Net capex for the quarter ~US$ 105 Million including investment of ~US$ 31 Million in PLI

105 Million

Profit at Rs 505.9 crore Basic & Diluted EPS is Rs 8.64 per share Net capex for the quarter ~US$ 105 Million including investment of ~US$ 31 Million in PLI project and capex of ~US$ 12 Million for various Ne